{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:17:43Z","timestamp":1788556663314,"version":"build-2803163510"},"reference-count":16,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,5,28]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>For unresectable stage III non-small-cell lung cancer (NSCLC), the optimal duration and regimen of consolidation immunotherapy following chemoradiation is unknown. Despite improved outcomes with 12 months of durvalumab, which has become the standard of care, new strategies to improve survival are needed. This study evaluates dual immunotherapy in the consolidation setting following concurrent chemoradiation as well as a shorter (6\u2009months) treatment duration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Following concurrent chemoradiation, subjects were randomized 1:1 to nivolumab alone (480\u2009mg intravenously every 4 weeks) or combination nivolumab (240\u2009mg intravenously every 2 weeks) and ipilimumab (1\u2009mg\/kg every 6 weeks) for up to 6 months. Primary endpoint was 18-month progression-free survival (PFS), and each arm was compared with appropriate historical controls. Secondary endpoints included overall survival (OS), time to metastatic disease, and toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>105 patients enrolled (54 nivolumab alone; 51 nivolumab\/ipilimumab). Median follow-up was 29.1 months for nivolumab and 30 months for nivolumab\/ipilimumab. For nivolumab alone, 18-month PFS was 65.5% (95% CI, 49.8% to 77.3%), a statistically significant improvement over the historical control of chemoradiation alone (p&lt;0.1). Median PFS was 29.7 months (95%\u2009CI, 16.5 to Not Reached), and median OS was 32 months (95%\u2009CI, 32 to NR). For nivolumab\/ipilimumab, 18-month PFS was 66.3% (95% CI, 56.3% to 74.5%), a statistically significant improvement over the historical control of chemoradiation followed by durvalumab (p&lt;0.1). Median PFS was 26.3 months (95%\u2009CI, 18.6 to NR), and median OS was not reached (95%\u2009CI, 30.9 to NR). Rate of any-grade treatment-related adverse events was 72.2% (grade \u22653=18.5%) for nivolumab and 80.4% (grade \u22653=29.4%) for nivolumab\/ipilimumab. Most common adverse events (grade 3\/4) for nivolumab were fatigue 31.5% (0%), pneumonitis 20.4% (7.4%), rash 16.7% (3.7%), dyspnea 14.8% (0%), and hypothyroidism 14.8% (0%). For nivolumab\/ipilimumab, they were fatigue 31.4% (3.9%), pneumonitis 23.5% (11.7%), diarrhea 19.6% (2%), dyspnea 19.6% (0%), pruritus 17.7% (0%), hypothyroidism 15.7% (0%), rash 15.7% (2%), arthralgias 11.8% (0%), and nausea 11.8% (0%). Grade 2 or higher pneumonitis was similar for nivolumab (20.4%) and nivolumab\/ipilimumab (19.6%), but grade 3 or higher pneumonitis was more common in the nivolumab\/ipilimumab arm (11.8% vs 7.4%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Despite only 6 months of consolidation immunotherapy, nivolumab alone and combination nivolumab\/ipilimumab both demonstrated improved 18-month PFS over appropriate historical controls. Overall toxicity, including grade 3 pneumonitis, was higher in the combination arm.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-010316","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:50:30Z","timestamp":1752580230000},"page":"e010316","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA\/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05221840","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04026412","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04380636","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-745X","authenticated-orcid":false,"given":"Greg","family":"Durm","sequence":"first","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-8703","authenticated-orcid":false,"given":"Hirva","family":"Mamdani","sequence":"additional","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Althouse","sequence":"additional","affiliation":[{"name":"Indiana University Richard M Fairbanks Department of Biostatistics, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Perkins","sequence":"additional","affiliation":[{"name":"Indiana University Richard M Fairbanks Department of Biostatistics, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma K","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apar Kishor","family":"Ganti","sequence":"additional","affiliation":[{"name":"Oncology-Hematology, University of Nebraska Medical Center, Omaha, Nebraska, USA"},{"name":"VA Nebraska-Western Iowa Health Care System, Grand Island, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadia","family":"Jalal","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA"},{"name":"Richard L Roudebush VA Medical Center, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0217-8278","authenticated-orcid":false,"given":"Jason","family":"Chesney","sequence":"additional","affiliation":[{"name":"University of Louisville School of Medicine, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-8686","authenticated-orcid":false,"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Beaumont Hospital, Dublin, Ireland"},{"name":"RCSI University of Health Sciences, Dublin, Ireland"},{"name":"Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borys","family":"Hrinczenko","sequence":"additional","affiliation":[{"name":"Michigan State University College of Human Medicine, East Lansing, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"Fidler","sequence":"additional","affiliation":[{"name":"Rush University Medical Center, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ticiana A","family":"Leal","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, Georgia, USA"},{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Feldman","sequence":"additional","affiliation":[{"name":"University of Illinois Cancer Center, Chicago, Illinois, USA"},{"name":"Jesse Brown VA Medical Center, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Fujioka","sequence":"additional","affiliation":[{"name":"University of Minnesota, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser H","family":"Hanna","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"2025100309500698000_13.7.e010316.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2543"},{"key":"2025100309500698000_13.7.e010316.2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33083"},{"key":"2025100309500698000_13.7.e010316.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"2025100309500698000_13.7.e010316.4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100309500698000_13.7.e010316.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231"},{"key":"2025100309500698000_13.7.e010316.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30641-0"},{"key":"2025100309500698000_13.7.e010316.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00975"},{"key":"2025100309500698000_13.7.e010316.8","doi-asserted-by":"crossref","first-page":"8534","DOI":"10.1200\/JCO.2022.40.16_suppl.8534","article-title":"Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non\u2013small cell lung cancer","volume":"40","author":"Jun","year":"2022","journal-title":"JCO"},{"key":"2025100309500698000_13.7.e010316.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.09.010"},{"key":"2025100309500698000_13.7.e010316.10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cllc.2020.12.014","article-title":"Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer","volume":"22","author":"Shukla","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"2025100309500698000_13.7.e010316.11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2022.04.033","article-title":"De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer","volume":"171","author":"Bryant","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025100309500698000_13.7.e010316.12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2021.12.176","article-title":"Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer","volume":"113","author":"Bryant","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100309500698000_13.7.e010316.13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.24478","article-title":"Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer","volume":"5","author":"Pichert","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025100309500698000_13.7.e010316.14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cllc.2024.07.013","article-title":"Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy","volume":"25","author":"Damhuis","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"2025100309500698000_13.7.e010316.15","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100309500698000_13.7.e010316.16","doi-asserted-by":"crossref","first-page":"102986","DOI":"10.1016\/j.esmoop.2024.102986","article-title":"LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2","volume":"9","author":"Bradley","year":"2024","journal-title":"ESMO Open"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:50:14Z","timestamp":1759510214000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,15]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/jitc-2024-010316"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010316","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}